Delhi HC sets aside order on Gilead’s Sovaldi patent
The Controller General of Patents, Designs and Trademarks had rejected a patent to the US drug maker for the hepatitis C drug
New Delhi: In a setback to generic drug makers, the Delhi high court on Friday set aside an order of the Deputy Controller of Patents and Designs rejecting a patent to US drug maker Gilead Pharmasset Llc for the hepatitis C drug Sovaldi.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more